Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tofacitinib tablet Clear all
Completed Phase 2 Interventional Results available

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NCT00147498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
24
States / cities
Upland, California • Clearwater, Florida • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Of Tofacitinib In Pediatric JIA Population

NCT02592434
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

NCT04111614
View directory record Official record
Conditions
Healthy
Interventions
Tofacitinib tablet, Tofacitinib Oral Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

NCT01393899
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Anaheim, California • Cypress, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

NCT01500551
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 18 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
43
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT03274076
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Tofacitinib, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated Early Phase 1 Interventional

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

NCT03159936
View directory record Official record
Conditions
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Interventions
Tofacitinib citrate
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

NCT01039688
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Disease-modifying antirheumatic drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
41
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Study of Tofacitinib in Refractory Dermatomyositis

NCT03002649
View directory record Official record
Conditions
Dermatomyositis
Interventions
Tofacitinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

NCT03281304
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CP-690,500 5 mg, CP-690,550 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
Mobile, Alabama • San Diego, California • Bristol, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

NCT00976599
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 + methotrexate, Placebo + Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Frederick, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

NCT01059864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

NCT02084875
View directory record Official record
Conditions
Healthy
Interventions
tofacitinib modified-release (MR) formulation
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed No phase listed Observational Results available

A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day

NCT04267380
View directory record Official record
Conditions
Arthritis Rheumatoid
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

NCT01470599
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 76 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
32
States / cities
Oceanside, California • Lafayette, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00678210
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

NCT00960440
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

NCT02312882
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Tofacitinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 26, 2026, 1:12 PM EDT